These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1066 related items for PubMed ID: 19855965

  • 1. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, Aul C, Schlegelberger B.
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [Abstract] [Full Text] [Related]

  • 2. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A.
    Clin Lymphoma Myeloma; 2009 Apr; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [Abstract] [Full Text] [Related]

  • 3. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
    Giagounidis AA, Haase S, Heinsch M, Göhring G, Schlegelberger B, Aul C.
    Ann Hematol; 2007 Feb; 86(2):133-7. PubMed ID: 17111142
    [Abstract] [Full Text] [Related]

  • 4. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
    Giagounidis AA.
    Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
    Oliva EN, Cuzzola M, Nobile F, Ronco F, D'Errigo MG, Laganà C, Morabito F, Galimberti S, Cortelezzi A, Aloe Spiriti MA, Specchia G, Poloni A, Breccia M, Ghio R, Finelli C, Iacopino P, Alimena G, Latagliata R.
    Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
    [Abstract] [Full Text] [Related]

  • 8. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
    Arcioni F, Roncadori A, Di Battista V, Tura S, Covezzoli A, Cundari S, Mecucci C, MORE Study Centres.
    Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
    Komrokji RS, List AF.
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C, Bacher U, Tiu R, Maciejewski JP, List A.
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [Abstract] [Full Text] [Related]

  • 13. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
    Melchert M, Kale V, List A.
    Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
    [Abstract] [Full Text] [Related]

  • 14. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG, Santana-Davila R, Dewald GW, Khetterling RP, Knudson RA, Hoyer JD, Chen D, Hanson CA, Porrata L, Tefferi A, Steensma DP.
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
    Sibon D, Cannas G, Baracco F, Prebet T, Vey N, Banos A, Besson C, Corm S, Blanc M, Slama B, Perrier H, Fenaux P, Wattel E, Groupe Francophone des Myélodysplasies.
    Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
    Balleisen S, Kuendgen A, Hildebrandt B, Haas R, Germing U.
    Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.